UK – NICE rejects NHS funding for Kyowa Kirin’s Poteligeo

NICE is not recommending NHS funding for Kyowa Kirin's Poteligeo (mogamulizumab) as a treatment for mycosis fungoides or Sézary syndrome for adults who have had at least one previous systemic treatment.

In preliminary guidelines, the Institute said clinical trial evidence is ‘very uncertain’ because mogamulizumab is compared with vorinostat, a treatment that is not used or licensed in the UK, where standard care for mycosis fungoides or Sézary syndrome in people who have had a least one previous systemic treatment includes methotrexate, bexarotene, interferon and chemotherapy.

Also, many people switch treatments and there are a lot of differences among the trial population, so it is unclear how well mogamulizumab works, NICE said.

The Institute also noted that the drug mogamulizumab does not meet NICE’s criteria to be considered a life-extending treatment at the end of life…